As of June 7, 2025, Horizon Therapeutics PLC (HZNP) reports a ROE (Return on Equity) of 10.28%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Horizon Therapeutics PLC's ROE (Return on Equity)
Over recent years, Horizon Therapeutics PLC's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-12-31 | 10.28% |
| 2021-12-31 | 11.44% |
| 2020-12-31 | 9.68% |
| 2019-12-31 | 26.22% |
| 2018-12-31 | -3.23% |
This slight downward trend highlights how Horizon Therapeutics PLC manages its efficiency in generating profits from shareholders' equity over time.
Comparing Horizon Therapeutics PLC's ROE (Return on Equity) to Peers
To better understand Horizon Therapeutics PLC's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Horizon Therapeutics PLC (HZNP) | 10.28% |
| Amneal Pharmaceuticals Inc (AMRX) | 106.97% |
| Endo International PLC (ENDP) | 49.30% |
| Harmony Biosciences Holdings Inc (HRMY) | 22.00% |
| Amphastar Pharmaceuticals Inc (AMPH) | 21.78% |
| Corcept Therapeutics Inc (CORT) | 20.78% |
Compared to its competitors, Horizon Therapeutics PLC's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.